Trilaciclib is a first-in-class, short-acting inhibitor of cyclin-dependent kinases 4 and 6. According to provided information, it is used to prevent bone marrow suppression caused by anticancer therapies.
Trilaciclib is a first-in-class, short-acting inhibitor of cyclin-dependent kinases 4 and 6. According to provided information, it is used to prevent bone marrow suppression caused by anticancer therapies.
